Patent intelligence · CA
CA 3025863
COMPOSE PHARMACEUTIQUE CONTENANT DU CEFUROXIME
COMPOSE PHARMACEUTIQUE CONTENANT DU CEFUROXIME
Patent details — CA 3025863
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jan 11, 2018
- Expiration
- Jan 6, 2038
- Applicant
- ACRAF [IT]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 47/ 10 A I, A61K 47/ 14 A I
Quick answer
CA 3025863 (COMPOSE PHARMACEUTIQUE CONTENANT DU CEFUROXIME) is held by ACRAF [IT]. Status: granted. Granted Jan 11, 2018. Expires Jan 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ACRAF [IT]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 47/ 10 A I, A61K 47/ 14 A I, A61K/31416, A61K/4710
More from ACRAF [IT]
Related pharmaceutical patents in our USPTO index.
-
EP 3807294
PEPTIDE MIT HEMMENDER WIRKUNG AUF MUSKARINREZEPTOR M3
granted -
EP 3807293
PEPTIDE MIT HEMMENDER WIRKUNG AUF NEURONALE EXOZYTOSE
granted -
CA 3135097
COMBINAISON PHARMACEUTIQUE COMPRENANT DE LA TRAZODONE POUR LE TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
granted -
WO 2020178316
AZAINDAZOLES EN 5 OU 7 UTILISÉS COMME INHIBITEURS DE BÊTA-LACTAMASE
granted -
WO 2020074463
COMPOSITION LIQUIDE ORALE COMPRENANT DU TRIPTAN
granted -
CA 3094896
COMPOSES DE 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE LA GLYCOGENE SYNTHASE KINASE 3 BETA
granted -
CA 3089552
PROCEDE CONTINU DE PREPARATION DE TRAZODONE
granted -
CA 3079530
COMPOSITION LIQUIDE STABLE DE KETOPROFENE, SELS ET ENANTIOMERES DE CELUI-CI
granted
Frequently asked questions
What is US patent 3025863?
CA 3025863 (COMPOSE PHARMACEUTIQUE CONTENANT DU CEFUROXIME) is held by ACRAF [IT]. Status: granted. Granted Jan 11, 2018. Expires Jan 6, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3025863?
ACRAF [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3025863 expire?
Our index shows an expiration date of Jan 6, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.